Blackstone, Carlyle Eye Joint Novartis Generics Unit Bid

Blackstone and Carlyle are considering a joint bid for Novartis' generics unit, valued at $25 billion. Novartis is exploring various options, including selling, spinning off, or retaining the unit. The company has been preparing for a potential separation by moving production and other functions. Sandoz, the generics unit, has faced challenges like price erosion and competition but shows potential in the biosimilar market.

What challenges has Novartis faced in the generic drugs market?

What potential does Novartis see in the biosimilar business?